EGFR and heart failure: Osimertinib, an inhibitor of EGFR in the ErbB/HER family, also demonstrates some activity against the HER2 receptor, which may contribute to its cardiotoxic effects, which may manifest as heart failure, left ventricular dysfunction, conduction abnormalities, and myocardial injury or dysfunction [119].